Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.

ABSTRACT:

Background

Tenofovir (TFV) gel partially protected against human immunodeficiency virus (HIV) in one but not subsequent trials. The disappointing results were attributed largely to poor adherence. However, timing of gel application relative to sex may impact pharmacokinetics and contribute to outcomes. Thus, we conducted a single-dose pharmacokinetic study of TFV gel applied 1 or 24 hours before or 1 hour before and 1 hour after (BAT) sex and compared results with dosing without sex.

Methods

Twenty-four couples were enrolled; cervicovaginal lavage (CVL) and tissue were collected 2 hours after sex with matching timed collections at no sex visits and assayed for drug concentrations and CVL anti-HIV activity.

Results

Compared with dosing without sex, median TFV concentra

SUBMITTER: Herold BC 

PROVIDER: S-EPMC4706638 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature